

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
154th Meeting of the Vaccines and Related Biological Products Advisory
Committee
FDA White Oak Campus, Building 31, Great Room
Salon B & C
Silver Spring, MD
November 8, 2018**

**AGENDA
Meeting Link:**

<https://collaboration.fda.gov/vrbpac1118/>

Topic : Presentation of the Laboratory of DNA Viruses (LDV), Division of Viral Products (DVP), Office of Vaccine Research and Review (OVR), Center for Biologics Evaluation and Research (CBER)

Note: Committee members are participating via teleconference

Time	Presentation/Presenter
11:00 AM	Opening Remarks: Call to Order, Introduction of Committee Arnold Monto, M.D. Acting Chair, VRBPAC Administrative Announcements, Conflict of Interest Statement Serina Hunter-Thomas, M.S.A., R.N. Designated Federal Officer, VRBPAC CBER, FDA
11:15 AM	Overview of Research/Site Visit Process, CBER (15 min) Carolyn Wilson, Ph.D. Associate Director for Research CBER/FDA
11:30 AM	Overview of DVP (15 min) Jerry Weir, Ph.D. Director, Division of Viral Products Office of Vaccines Research and Review
11:45 AM	Overview of LDV (15 min) Keith Peden, Ph.D. Principal Investigator Laboratory of DNA Viruses CBER/FDA/OVR/DVP
12:00 PM	Break (15 min)
12:15 PM	Open Public Hearing (60 min)
1:15 PM	Conflict of Interest Statement (5 min) Serina Hunter-Thomas, M.S.A., R.N. Designated Federal Officer VRBPAC
1:20 PM	Closed Session (50 min)
2:10 PM	Adjourn Meeting